Thus, the data from this work elucidating potential immunologic correlates for improved anti-tumor response in preclinical models together with a suggestion of improved overall survival in the clinic support further clinical investigation of combination poxvirus-based active immunotherapy together with CTLA-4 immune checkpoint inhibition in prostate cancer and other cancers. Here, CTLA4 is linked to cancer.